Pandion Therapeutics has signed a license and collaboration deal worth up to $790m with Japan-based Astellas Pharma to research, develop, and commercialise locally acting immunomodulators for autoimmune diseases of the pancreas.
Seattle Genetics is known best for Adcetris, a cancer drug and its only approved product. Results from two studies presented over the weekend suggest the Bothell, Washington-based biotech's future could be more diversified.
Astellas and Seattle Genetics’ antibody-drug conjugate is at it again. On Saturday, the duo revealed data showing that enfortumab vedotin, along with Merck’s Keytruda, shrank 71% of tumors and wiped out 13% of them in patients with advanced urothelial cancer who had not undergone any other cancer treatment.
Astellas’ FLT3 inhibitor for acute myeloid leukaemia (AML) – Xospata – has been recommended for approval in Europe, giving it a further lead over a rival drug from Daiichi Sankyo.
Less than a year after scoring a fast FDA OK for its pioneering acute myeloid leukemia drug gilteritinib, Astellas has snapped up a positive recommendation from European regulators following an accelerated assessment.
Patient centricity can seem like just another pharma buzzword, but Astellas is working to put its money where its mouth is.
The Japanese drugmaker tapped its first "centricity"-focused exec—Anthony Yanni, recruited from Sanofi—to helm its efforts to pull in patient perspectives from drug discovery to market.
Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to a new move from the FDA, they might not have to wait that long. Wednesday, the agency bestowed priority review on their application for use in metastatic, hormone-sensitive prostate cancer.
Astellas has teamed up with Tokyo University of the Arts and Yokohama City University to create and commercialise new digital healthcare solutions using gamification.
Japan’s Astellas has started treating patients in a phase 3 trial of fezolinetant, a non-hormonal drug for menopausal symptoms that the company views as a big growth prospect in the coming years.
Frequency Therapeutics has raised $62 million to take its Astellas-partnered hearing loss drug into phase 2a. The series C is the latest in a series of boosts for Frequency’s attempts to tackle hearing loss through the activation of progenitor cells.